Latest Period
Q2 2026
Security Snapshot
Axsome Therapeutics, Inc. - Common Stock (AXSM) Institutional Ownership
CUSIP: 05464T104
13F Institutional Holders and Ownership History from Q4 2015 to Q2 2026
Institutions Reporting
503
Shares (Excl. Options)
38,197,813
Price
$244.77
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- AXSM on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 38,197,813
- Total 13F value
- $9,341,408,838
- Portfolio coverage rank
- 0.02%
- Share change
- +235,101
- Value change
- +$79,179,840
- Number of holders
- 503
- Shares outstanding
- 51,632,132
- SEC-reported price per share
- $234.20
- Insider filing price
- $234.20
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- AXSM - Axsome Therapeutics, Inc. - Common Stock is tracked under CUSIP 05464T104.
- 503 institutions reported positions in Q2 2026.
- 2 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 410 to 503 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $6,405,611,688 to $9,341,408,838.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 503 institutions filings for Q2 2026.
Security key
05464T104
Latest holder period
Q2 2026
13F holders
503
13D/G owners
2
CIK / CUSIP context first
Open Q2 2026 holders
AXSM full holder history
Axsome Therapeutics, Inc. SEC filings
Axsome Therapeutics, Inc. company facts
Axsome Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 05464T104:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
2
Security
AXSM
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 5.3% | $669,813,839 | 2,736,503 | BlackRock, Inc. | 30 Jun 2026 | |||
| RTW INVESTMENTS, LP | 3.1% | -48% | $165,312,089 | -$153,206,917 | 1,516,903 | -48% | RTW Investments, LP | 30 Jun 2025 |
As of 30 Jun 2026, 503 institutional investors reported holding 38,197,813 shares of Axsome Therapeutics, Inc. - Common Stock (AXSM). This represents 74% of the company’s total 51,632,132 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
43%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 6% | 3,103,708 | -21% | 0.01% | $759,694,607 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 3.8% | 1,983,514 | -3.6% | 0.02% | $485,504,722 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.8% | 1,965,086 | +1.4% | 0.01% | $480,994,100 |
| Invesco Ltd. | 3.2% | 1,671,684 | +29% | 0.03% | $409,178,095 |
| FMR LLC | 3% | 1,539,163 | -1.8% | 0.02% | $376,740,965 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.9% | 967,172 | -17% | 0.01% | $236,786,194 |
| MORGAN STANLEY | 1.6% | 804,081 | +69% | 0.01% | $196,815,060 |
| STATE STREET CORP | 1.5% | 785,661 | -20% | 0.01% | $192,289,814 |
| Deep Track Capital, LP | 1.4% | 700,000 | -36% | 2.5% | $171,339,000 |
| TWO SIGMA INVESTMENTS, LP | 1.3% | 669,478 | +107% | 0.12% | $163,868,130 |
| FRANKLIN RESOURCES INC | 1.3% | 668,373 | +52% | 0.04% | $163,597,660 |
| WELLINGTON MANAGEMENT GROUP LLP | 1.3% | 653,920 | -43% | 0.03% | $160,059,998 |
| ALETHEA CAPITAL MANAGEMENT, LLC | 1.3% | 648,756 | -0.06% | 66% | $158,796,006 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.2% | 642,893 | -51% | 0.02% | $157,362,000 |
| D. E. Shaw & Co., Inc. | 1.2% | 604,753 | +0.21% | 0.09% | $148,025,392 |
| MILLENNIUM MANAGEMENT LLC | 1.1% | 556,088 | +2579% | 0.09% | $136,113,660 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 1% | 539,407 | -34% | 0.2% | $132,031,000 |
| NORGES BANK | 1% | 514,266 | 0.01% | $125,876,889 | |
| FIRST TRUST ADVISORS LP | 0.93% | 482,061 | -17% | 0.07% | $117,994,070 |
| Assenagon Asset Management S.A. | 0.88% | 454,682 | -47% | 0.14% | $111,292,513 |
| BANK OF AMERICA CORP /DE/ | 0.88% | 452,491 | -24% | 0.01% | $110,756,330 |
| AMERIPRISE FINANCIAL INC | 0.83% | 428,079 | +143% | 0.02% | $104,781,493 |
| Pictet Asset Management Holding SA | 0.83% | 426,527 | +2.5% | 0.1% | $104,399,930 |
| Qube Research & Technologies Ltd | 0.83% | 426,336 | +27% | 0.12% | $104,354,263 |
| Point72 Asset Management, L.P. | 0.81% | 416,516 | -1.9% | 0.16% | $101,950,621 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
43
Latest
Q2 2026
Rows shown
1-25 of 43
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 38,197,813 | $9,341,408,838 | +$79,179,840 | $244.77 | 503 |
| 2026 Q1 | 37,913,881 | $6,405,611,688 | +$6,714,730 | $169.02 | 410 |
| 2025 Q4 | 37,608,367 | $6,859,715,837 | +$12,741,708 | $182.64 | 398 |
| 2025 Q3 | 37,169,613 | $4,513,412,476 | -$67,590,005 | $121.45 | 352 |
| 2025 Q2 | 37,843,872 | $3,950,044,159 | +$74,087,650 | $104.39 | 345 |
| 2025 Q1 | 36,999,749 | $4,315,367,902 | +$55,229,563 | $116.63 | 349 |
| 2024 Q4 | 37,175,235 | $3,145,106,906 | -$176,513,164 | $84.61 | 290 |
| 2024 Q3 | 38,678,079 | $3,475,093,026 | -$190,434,872 | $89.87 | 277 |
| 2024 Q2 | 40,712,369 | $3,277,256,100 | +$165,407,783 | $80.50 | 253 |
| 2024 Q1 | 38,735,398 | $3,089,970,732 | +$16,979,676 | $79.80 | 254 |
| 2023 Q4 | 38,597,370 | $3,071,777,083 | +$30,855,225 | $79.59 | 242 |
| 2023 Q3 | 37,879,928 | $2,647,367,402 | +$88,702,381 | $69.89 | 224 |
| 2023 Q2 | 36,371,724 | $2,613,474,662 | +$329,094,500 | $71.86 | 227 |
| 2023 Q1 | 31,901,760 | $1,967,140,427 | +$94,141,631 | $61.68 | 194 |
| 2022 Q4 | 30,053,540 | $2,317,913,385 | +$384,566,478 | $77.13 | 213 |
| 2022 Q3 | 25,705,114 | $1,146,849,855 | +$196,048,585 | $44.62 | 180 |
| 2022 Q2 | 21,590,557 | $826,608,565 | +$90,967,881 | $38.30 | 164 |
| 2022 Q1 | 19,105,701 | $787,305,601 | +$28,307,048 | $41.39 | 165 |
| 2021 Q4 | 18,632,401 | $703,886,639 | -$18,569,388 | $37.78 | 161 |
| 2021 Q3 | 19,030,753 | $625,717,799 | -$187,658,523 | $32.96 | 165 |
| 2021 Q2 | 22,332,926 | $1,506,651,537 | -$37,805,529 | $67.46 | 172 |
| 2021 Q1 | 22,937,308 | $1,299,681,826 | -$60,738,349 | $56.62 | 181 |
| 2020 Q4 | 23,974,672 | $1,951,921,924 | -$4,134,242 | $81.47 | 178 |
| 2020 Q3 | 24,031,769 | $1,711,934,785 | -$21,143,954 | $71.25 | 171 |
| 2020 Q2 | 24,239,746 | $1,992,911,051 | +$152,460,166 | $82.28 | 188 |